Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$40.36 USD
-0.56 (-1.37%)
Updated Oct 14, 2025 03:55 PM ET
After-Market: $40.22 -0.14 (-0.35%) 4:12 PM ET
5-Strong Sell of 5 5
D Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Agios Pharmaceuticals, Inc.'s return on equity, or ROE, is -3.49% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that AGIO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
AGIO 40.36 -0.56(-1.37%)
Will AGIO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
Other News for AGIO
AGIO's price rises by 0.76% on October 13, though its technical setup remains stable.
AGIO forms Slingshot Bullish on October 10
AGIO forms Upper Bollinger Band Walk on October 9
COMMODORE CAPITAL LP Acquires Significant Stake in SAB Biotherapeutics Inc
AGIO rises 4.23% on October 8, leaving the technical picture intact